Hematology · IDH InhibitionTrial Updateclinicalmid-term

Eli Lilly initiates Phase 1 trial of oral IDH inhibitor LY3410738 in hematologic malignancies

Importance7/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

Eli Lilly56 signalsView page

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/4/2026, 12:32:49 AM

Assessment confidence: 78% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

The initiation of Eli Lilly's Phase 1 trial for LY3410738 is significant as it targets a specific patient population with limited treatment options. Success in this trial could strengthen Eli Lilly's oncology portfolio and position it competitively in the targeted therapy market for hematologic cancers. Regulatory context from MHRA (ACE-inhibitors: Be aware of the distinction between bradykinin- and histamine-mediated angioedema, as treatment strategies differ significantly) supports the near-term read. Assessment grounded in 15 ranked evidence items (11 high-relevance).

Strategic Assessment

The success of this trial could enhance Eli Lilly's portfolio in oncology and provide a new treatment option for patients with limited therapies. The strongest clinical anchor is Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations (ClinicalTrials.gov), entity match (eli lilly); patient population match (advanced). In Hematology · IDH Inhibition, 4 regulatory and 1 competitive items passed relevance filtering for Eli Lilly.

Competitive Pressure

The most relevant competitive pressure comes from Roche's ENSPRYNG shows 68% relapse reduction in Phase III MOGAD study (Humanexa Signals) — sponsor/company relevance (roche). This trial positions Eli Lilly in the competitive landscape of targeted therapies for hematologic cancers, particularly in a niche of IDH-mutant patients.

Regulatory Outlook

Regulatory risk is concentrated around ACE-inhibitors: Be aware of the distinction between bradykinin- and histamine-mediated angioedema, as treatment strategies differ significantly (MHRA). Sponsor/company relevance (Lilly); Regulatory pathway relevance (nda). Relevant agencies in corpus: MHRA, FDA. The trial's outcomes will be critical for future regulatory submissions, influencing approval timelines and labeling for IDH inhibitors in hematologic malignancies.

Key Risks

Elevated medium regulatory exposure for Eli Lilly could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

If successful, LY3410738 could capture market share in a niche segment of hematologic malignancies, potentially leading to increased revenue streams for Eli Lilly.
Upside for Eli Lilly may improve if Phase I Trial of Pacritinib in Combination With Venetoclax and Azacitidine for the Treatment of Accelerated and Blast Phase Myeloproliferative Neoplasms (ClinicalTrials.gov) delivers favorable follow-through.
Lead sponsor: AstraZeneca. This is a modular, multicentre, open-label, Phase I/II, dose-setting study. AZD9829 will be administered intravenously as monotherapy or in combination in participants with CD123 positive hematological malignancies.
The success of this trial could enhance Eli Lilly's portfolio in oncology and provide a new treatment option for patients with limited therapies.

What Would Change This Assessment

This becomes more urgent if Monitor trial enrollment rates and initial safety data as well as potential competitive responses from other companies targeting IDH mutations.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

ACE-inhibitors: Be aware of the distinction between bradykinin- and histamine-mediated angioedema, as treatment strategies differ significantly
MHRAhigh relevance
Sponsor/company relevance (Lilly); Regulatory pathway relevance (nda)
FDA document
View source
Drug Trials Snapshots: YARTEMLEA
FDAhigh relevance
Sponsor/company relevance (Lilly)
FDA document
View source
FDA Actions to Accelerate and Modernize Early and Late-Stage Clinical Development
FDAhigh relevance
Sponsor/company relevance (Lilly)
FDA document
View source
Janus Kinase (JAK) inhibitors: Drug Safety Communication - FDA Requires Warnings about Increased Risk of Serious Heart-related Events, Cancer, Blood Clots, and Death
FDAhigh relevance
Sponsor/company relevance (Lilly)
FDA document
View source

Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations
ClinicalTrials.govhigh relevance
Entity match (eli lilly); Patient population match (advanced)
FDA document
View source
Phase I Trial of Pacritinib in Combination With Venetoclax and Azacitidine for the Treatment of Accelerated and Blast Phase Myeloproliferative Neoplasms
ClinicalTrials.govmedium relevance
Sponsor/company relevance (Lilly)
FDA document
View source
Study of AZD9829 in CD123+ Hematological Malignancies
ClinicalTrials.govmedium relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source
Use of Custom-Made Acrylic Palatal Stent to Minimize Donor Site Morbidity After Suture-Free Epithelialized Gingival Graft Harvesting: A Randomized Clinical Trial
ClinicalTrials.govmedium relevance
Sponsor/company relevance (Lilly)
FDA document
View source

Roche's ENSPRYNG shows 68% relapse reduction in Phase III MOGAD study
Humanexa Signalsmedium relevance
Sponsor/company relevance (Roche)

Efficacy of vunakizumab in patients with moderate-to-severe plaque psoriasis across diverse disease features: a post hoc analysis of a phase-III trial.
PubMedhigh relevance
Sponsor/company relevance (Lilly)
FDA document
View source
Do subjective and objective baseline sleep disturbances predict post-traumatic stress disorder treatment response? A secondary analysis of a randomized controlled trial.
PubMedhigh relevance
Sponsor/company relevance (Lilly)
FDA document
View source
Oral self-assembly nanoemulsion drives in vivo hepatic stellate cell-targeting drug delivery in liver fibrosis.
PubMedhigh relevance
Sponsor/company relevance (Lilly)
FDA document
View source
Effects of acute HMB-FA supplementation on antioxidant status and muscle damage in Elite Judoka: a randomized pilot trial.
PubMedhigh relevance
Sponsor/company relevance (Lilly)
FDA document
View source
RBM15B-mediated m6A modification of FOXM1 activates the AURKA/TPX2 axis to promote epithelial-mesenchymal transition-driven endometrial cancer progression.
PubMedhigh relevance
Sponsor/company relevance (Lilly)
FDA document
View source
Systematic identification of bacterial neuraminidase inhibitors from Psoralea corylifolia using ultrafiltration-UPLC-Q-Orbitrap-MS and molecular dynamics.
PubMedhigh relevance
Sponsor/company relevance (Lilly)
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Eli Lilly

Commercial impact

medium

If successful, LY3410738 could capture market share in a niche segment of hematologic malignancies, potentially leading to increased revenue streams for Eli Lilly.

Regulatory impact

medium

The trial's outcomes will be critical for future regulatory submissions, influencing approval timelines and labeling for IDH inhibitors in hematologic malignancies.

What to watch

Monitor trial enrollment rates and initial safety data as well as potential competitive responses from other companies targeting IDH mutations.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.